logo
Parse-Enabled Study Maps Neuronal Pathways with Potential Implications for Neurodegenerative Disease Research

Parse-Enabled Study Maps Neuronal Pathways with Potential Implications for Neurodegenerative Disease Research

National Post10-07-2025
Article content
SEATTLE — Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced a groundbreaking study published in the journal Science that utilized Parse's single cell technology to uncover how signaling pathways drive the formation of diverse neuron cell subtypes. By linking specific signals to cell fate outcomes, this research provides a powerful framework for generating defined cell types in vitro, which has broad relevance to human biology, disease, and therapeutic development.
Article content
Principle investigators Dr. Barbara Treutlein, Head of the Quantitative Development Biology Lab at ETH Zurich, and Dr. Gray Camp, Group Leader at the Institute of Human Biology at Roche, led the experiment.
Article content
Through an elegantly designed screening approach spanning 480 morphogens across 700,000 cells, the research team was able to explore how different morphogens interact with pro-neural transcription factors, thereby generating pure populations of different types of neurons from pluripotent stem cells. This work will guide and enable the neuroscience research community to direct and develop pure neuronal cell populations which will help expand our understanding of cell types and cell interactions implicated in neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS.
'We were genuinely surprised by the diversity of neurons that we generated, and the data allowed us to develop algorithms to learn how this diversity can arise,' states Treutlein. 'Parse Biosciences' technology delivered the flexibility, scale, and quality to help us explore these complex cellular processes at a deeper level.'
Article content
'The beauty of this work is that the underlying strategy, methods, and analyses can be adapted to program and explore any cell type and state, across organ systems and species,' states Camp. 'We are excited about what Parse's technology has enabled for this study.'
Article content
'We are thrilled to support this highly impactful study from Dr. Treutlein's and Dr. Camp's Labs and are eager to see how their findings inform the wider research community,' states Dr. Charlie Roco, Chief Technology Officer of Parse Biosciences.
Article content
About Parse Biosciences
Article content
Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.
Article content
With technology developed at the University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $100 million in capital and is used by 3,000 customers across the world. Its growing portfolio of products includes Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR, Gene Select, and a solution for data analysis, Trailmaker™.
Article content
Article content
Article content
Article content
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Globe and Mail

timean hour ago

  • Globe and Mail

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

SEATTLE, July 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ('Perspective' or the 'Company') (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [ 212 Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2025 taking place October 17 to 21, 2025 in Berlin, Germany. ESMO plans to release further details for regular abstracts on October 13, 2025. About [ 212 Pb]VMT-α-NET Perspective designed [ 212 Pb]VMT-α-NET to target and deliver 212 Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study ( identifier NCT05636618) of [ 212 Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol. About Perspective Therapeutics, Inc. Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212 Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET) and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212 Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations. For more information, please visit the Company's website at Safe Harbor Statement This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's plans and the expected timing for the release of additional data from its clinical programs; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212 Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting moieties provide the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212 Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact. The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Cascade Space Announces $5.9M Seed Funding to Build End-To-End Space Communication Platform
Cascade Space Announces $5.9M Seed Funding to Build End-To-End Space Communication Platform

National Post

time2 hours ago

  • National Post

Cascade Space Announces $5.9M Seed Funding to Build End-To-End Space Communication Platform

SAN FRANCISCO — Cascade Space, the platform for end-to-end communication system design, test, and operation, today announced that it has raised $5.9 million in seed funding. The round included participation from Nova Threshold, Undeterred Capital, Y Combinator, Night Capital, Olive Capital, Valkyrie Ventures, Karman Ventures, Palm Drive Capital, Garage Capital, TRAC, Aurelia Foundry, Hawktail, Pioneer Fund, Liquid 2 Ventures, and others. THIS CONTENT IS RESERVED FOR SUBSCRIBERS Enjoy the latest local, national and international news. Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events. Unlimited online access to National Post. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles including the New York Times Crossword. Support local journalism. SUBSCRIBE FOR MORE ARTICLES Enjoy the latest local, national and international news. Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events. Unlimited online access to National Post. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors The funding will accelerate the development of the Cascade Portal, a platform for satellite communication system design. Cascade recently released the spacelink Python library open-source. This library contains functions for communication system analysis that is used in the Cascade Portal implementation. 'Our mission at Cascade Space is to provide tools and infrastructure for spacecraft communication system design, test, and operations that will allow our customers to ship faster with the highest levels of mission assurance,' said Jacob Portukalian, co-founder and CEO of Cascade. 'Communication system design, test, and operation is a major bottleneck for space companies, especially those going to lunar and deep space. We have a team of veteran space engineers from SpaceX and Astra and we are stoked to be building the end-to-end platform to accelerate space exploration.' Cascade Space is a space communication system company. Founded in 2025, Cascade Space is building the platform for design, test, and operation for space communication systems. For more information, visit View source version on Jacob Portukalian Co-Founder / CEO jacob@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store